Inflammatory Dermatoses?
ORYVE® IT
RELIEVE IT
ZORYVE  has the power and
versatility to be your go-to topical.1,2
Not a steroid. No boxed warning
Simple once-daily treatment
Simple once-daily treatment
ZORYVE (roflumilast) Cream 0.05%, ZORYVE (roflumilast) Cream 0.15%, ZORYVE (roflumilast) Cream 0.3%, and ZORYVE (roflumilast) Topical Foam 0.3%
PLAQUE
PSORIASIS

Cream 0.3% for age 2+
Foam 0.3% for age 12+

ATOPIC
DERMATITIS

Cream 0.15% for age 6+
Cream 0.05% for age 2–5

SEBORRHEIC
DERMATITIS

Foam 0.3% for age 9+

Not actual patients. Symptoms illustrated.

Powerful skin clearance
and rapid itch relief,
from head to toe1–3
Established safety profile for
long-term use4–6,16
#1 prescribed branded topical
across 3 major chronic inflammatory
dermatoses combined8

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.

PLAQUE PSORIASIS: 40% of patients achieved IGA Success with ZORYVE cream 0.3% at Week 8 vs 7% with vehicle. 69% of patients achieved WI-NRS Success at Week 8 with ZORYVE cream 0.3% vs 31% with vehicle. 63% of patients achieved S-IGA Success with ZORYVE foam at Week 8 vs 21% with vehicle. 42% of patients achieved B-IGA Success with ZORYVE foam at Week 8 vs 15% with vehicle. In ARRECTOR, 65% of patients achieved SI-NRS Success at Week 8 with ZORYVE foam vs 30% with vehicle, 63% of patients experienced WI-NRS Success at Week 8 with ZORYVE foam vs 30% vehicle.1,2,8-10

ATOPIC DERMATITIS: 31% of patients achieved vIGA-AD Success at Week 4 with ZORYVE cream 0.15% vs 14% with vehicle. 32% of patients achieved WI-NRS Success at Week 4 with ZORYVE cream 0.15% vs 17% with vehicle. 25% of patients achieved vIGA-AD Success with ZORYVE cream 0.05% at Week 4 vs 11% with vehicle.1,11

SEBORRHEIC DERMATITIS: 77% of patients achieved IGA Success with ZORYVE foam at Week 8 vs 53% with vehicle. In STRATUM, 63% of patients achieved WI-NRS Success at Week 8 with ZORYVE foam vs 41% with vehicle.2,8,12

See the study design below.

Results of the primary analyses are from a pooled analysis of DERMIS-1 and DERMIS-2 for ZORYVE cream 0.3% in patients with plaque psoriasis, ARRECTOR and Trial 204 for ZORYVE foam 0.3% in patients with plaque psoriasis, INTEGUMENT-1 and INTEGUMENT-2 for ZORYVE cream 0.15% in patients with atopic dermatitis, and STRATUM and Trial 203 for ZORYVE foam 0.3% in patients with seborrheic dermatitis. Results should be interpreted in the context of individual study designs and analysis populations.